Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated LDH, and site of disease are prognostic of poor overall survival for patients with advanced melanoma treated with pembrolizumab.
https://ift.tt/2LP5NEU
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου